This site is for US healthcare professionals to provide online access to current, accurate, scientific information about our products. It is prepared by Janssen Medical Information and is not intended for promotional purposes, nor for medical advice.

  1. Home
  2. Announcements
  3. Selected Announcement

Report an AE/PQC

SYMTUZA® (darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide) Dear Healthcare Professional Letter, December 2020

A Dear Healthcare Professional Letter was issued for SYMTUZA® (darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide) in December 2020.

Please view the full Prescribing Information, including BOXED WARNING, for SYMTUZA® (darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide).

For product-related questions, please call our contact center at 1-800-Janssen (1-800-526-7736), or email your Medical Information Request and a response will be provided promptly.

Announcements

Resources

Report an Adverse Event
Report a Product Quality Complaint

Who are our experts?

Pharmacists or Nurses who are specifically trained on all aspects of the Janssen products and the therapeutic areas they treat.

Need Help?

Scientific Knowledge Experts are available Monday-Friday 9am-8pm ET

Call 1-800-JANSSEN
Email My Inquiry
Chat Live (For Selected Products)
Locate My Medical
Science Liaison